BDP9066 |
| Catalog No.GC33340 |
BDP9066 est un inhibiteur puissant et sélectif de la kinase de liaison Cdc42 liée À la dystrophie myotonique avec une IC50 de 64 nM pour MRCKβ dans les cellules SCC12, des valeurs Ki de 0,0136 nM et 0,0233 nM pour MRCKα/β dans les déterminations internes, respectivement. Le BDP9066 a un effet thérapeutique sur le cancer de la peau en réduisant la phosphorylation du substrat.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2226507-04-4
Sample solution is provided at 25 µL, 10mM.
BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinases MRCK inhibitor with an IC50 of 64 nM for MRCKβ in SCC12 cells, Ki values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation.
BDP9066 shows antiproliferative effects with greatest activity in hematologic cancer cells. BDP9066 inhibits MLC phosphorylation and blocks SCC12 squamous cell carcinoma motility and invasion[1].
BDP9066 topical application significantly decreases phosphorylated MRCKα S1003 staining and tumor volumes[1].
[1]. Unbekandt M, et al. Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer. Cancer Res. 2018 Apr 15;78(8):2096-2114.
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *